Abstract
Cryptococcus neoformans is the most common cause of fungal meningitis in HIV and non-HIV-infected patients. The organism has a worldwide distribution, with cases typically occurring among patients with well-recognized specific underlying disorders associated with dysfunction of cellmediated immunity. While the therapy for disease was studied extensively in the 1970s and the 1980s among non-HIV-infected individuals, most of the recently published data have concerned therapy for central nervous system cryptococcosis in HIV-infected patients. As a result, the current approach to therapy for central nervous system cryptococcosis in the non-HIV-infected patient represents a hybrid of the established “gold standard,” which includes at least 6 weeks of combination therapy with amphotericin B and 5-flucytosine, and the more contemporary regimen, which consists of 2 weeks of induction therapy with an amphotericin B-containing regimen followed by fluconazole. Clearly, well-designed prospective studies are needed to define the best approach to therapy in these patients, but until then, we must rely on the results of the existing clinical trials and carefully interpret the results of the available retrospective data. At present, amphotericin B (deoxycholate or lipid-associated) is recommended as initial therapy for all non-HIV-infected patients with proven or suspected cryptococcal meningitis. Fluconazole plays an important role in consolidation therapy and among selected patients who require long-term chronic suppression. The potential role of the newer triazoles (voriconazole and posaconazole) is undetermined.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Levitz SM: The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991, 13:1163–1169.
Duperval R, Hermans PE, Brewer NS, Roberts GD: Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 1977, 72:13–19.
Perfect JR, Durack DT, Gallis HA: Cryptococcemia. Medicine 1983, 62:98–109.
Cryptococcosis. In Medical Mycology. Edited by Kwon Chung KJ, Bennett JE. Philadelphia: Lea and Febiger; 1992:397–446.
Dismukes WE: Cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1988, 157:624–628.
Diamond RD, Bennett JE: Prognostic factors in cryptococcal meningitis. Ann Intern Med 1974, 80:176–181.
Bennett JE, Dismukes WE, Duma RJ, et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979, 301:126–131.
Dismukes WE, Cloud G, Gallis HA, et al.: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334–341.
Diamond RD, Bennett JE: Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J Infect Dis 1973, 127:694–697.
Graybill JR, Alford RH: Cell-mediated immunity in cryptococcosis. Cell Immunol 1974, 14:12–21.
Schimpff SC, Bennett JE: Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol 1975, 55:430–441.
Sorensen RN, Boehm KD, Kaplan D, Berger M: Cryptococcal osteomyelitis and cellular immunodeficiency associated with interleukin-2 deficiency. J Pediatr 1992, 121:873–879.
Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83–89.
van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15–21.
Galgiani JN: Fluconazole, a new antifungal agent. Ann Intern Med 1990, 113:177–179.
Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28(2):297–298. This study evaluated patients receiving either fluconazole 200 mg/d or itraconazole 200 mg/d as chronic maintenance therapy among HIV patients who had responded to a 10-week induction course of therapy. It established that at the doses studied, fluconazole was clearly superior to itraconazole in preventing relapse, and established fluconazole as the drug of choice for chronic suppressive therapy.
Pappas PG, Hamill RJ, Kauffman CA, et al., and members of the NIAID Mycoses Study Group: Treatment of cryptococcal meningitis in non-HIV infected patients — a randomized comparative trial. Paper presented at Infectious Disease Society of America. September 18–20, 1996. New Orleans, LA.
Dromer F, Mathoulin S, Dupont B, et al., and the French Cryptococcosis Study Group. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis 1996, 22(suppl 2):S154-S160.
Pappas PG, Perfect JR, Cloud GA, et al.: Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, In press. This is the largest of the retrospective studies evaluating the current management of cryptococcosis in non-HIV-infected patients. The review includes 157 patients with CNS cryptococcosis. In contrast to the paper by Dromer et al. [18], most patients in this study received amphotericin B plus 5-flucytosine for approximately 1 month, followed by fluconazole for approximately 10 weeks. Success rates were approximately 80% consistent with the previously published data.
Park MK, Hospenthal DR, Bennett JE: Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999, 28:629–633. This is a retrospective review of 10 patients who underwent permanent ventricular shunting procedures for hydrocephalus associated with CNS cryptococcosis. The study suggested that there was no evidence of dissemination of infection, nor was there evidence to suggest persistent catheter-associated infection caused by C. neoformans.
Saag MS, Graybill RJ, Larsen RA, et al.: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710–718. These guidelines represent a consensus approach to the treatment of all forms of cryptococcosis based on published literature and the consensus opinion of the writing committee. It should be emphasized that these are guidelines, and that specific therapy must be individualized on a patient-by-patient basis.
Hamill RJ, Sobel J, El-Sadr W, et al.: Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Paper presented at Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26–29, 1999. San Francisco, CA.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pappas, P.G. Therapy of cryptococcal meningitis in non-HIV-infected patients. Curr Infect Dis Rep 3, 365–370 (2001). https://doi.org/10.1007/s11908-001-0077-5
Issue Date:
DOI: https://doi.org/10.1007/s11908-001-0077-5